Kleanthis G. Xanthopoulos
2012 - Regulus Therapeutics
In 2012, Kleanthis G. Xanthopoulos earned a total compensation of $1.5M as President and Chief Executive Officer at Regulus Therapeutics, a 116% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $348,748 |
|---|---|
| Option Awards | $648,387 |
| Salary | $515,500 |
| Other | $4,368 |
| Total | $1,517,003 |
Xanthopoulos received $648.4K in option awards, accounting for 43% of the total pay in 2012.
Xanthopoulos also received $348.7K in non-equity incentive plan, $515.5K in salary and $4.4K in other compensation.
Rankings
In 2012, Kleanthis G. Xanthopoulos' compensation ranked 4,532nd out of 11,487 executives tracked by ExecPay. In other words, Xanthopoulos earned more than 60.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,532 out of 11,487 | 61st |
Division Manufacturing | 1,574 out of 4,253 | 63rd |
Major group Chemicals And Allied Products | 361 out of 1,203 | 70th |
Industry group Drugs | 225 out of 925 | 76th |
Industry Pharmaceutical Preparations | 174 out of 700 | 75th |
Source: SEC filing on April 30, 2013.
Xanthopoulos' colleagues
We found two more compensation records of executives who worked with Kleanthis G. Xanthopoulos at Regulus Therapeutics in 2012.